Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy

Mise à jour : Il y a 4 ans
Référence : NCT00347698

Femme et Homme

  • | Pays :
  • Mexico
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of the study is to evaluate the safety and efficacy of 2.5 mg of intravitreal bevacizumab in one eye, versus panretinal photocoagulation in the contralateral eye, for the treatment of patients with untreated symmetric proliferative diabetic retinopathy.


Critère d'inclusion

  • Diabetic retinopathy

Liens